Sandoz Lawsuit Vs. European Commission Highlights Uncertainties Over Biogenerics

Law360, New York (April 8, 2004, 12:00 AM EDT) -- In a case likely to have broad implications, Swiss generic drug maker Sandoz has filed a lawsuit against the European Commission for denying approval of the world’s first generic biotech drug.

In a decision that took the market by surprise, the European Union’s executive body rejected Sandoz’ application of its Omnitrop generic human growth hormone, citing filing irregularities.

However, Sandoz says it believes it used an appropriate pathway to file the drug, and officials told the media they were engaged in an ongoing dialogue with the...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.